Literature DB >> 15402609

Neurotoxicity of the 8-aminoquinolines; reactions of various experimental animals to plasmocid.

I G SCHMIDT, L H SCHMIDT.   

Abstract

Entities:  

Keywords:  QUINOLINE

Mesh:

Substances:

Year:  1949        PMID: 15402609     DOI: 10.1002/cne.900910303

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


× No keyword cloud information.
  6 in total

1.  Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys.

Authors:  L H Schmidt
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

2.  Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).

Authors:  Gary Rockwood; Steven Duniho; Crystal Briscoe; Mark Gold; Kevin Armstrong; David Kahler; Anita Moran; Steven Baskin
Journal:  J Med Toxicol       Date:  2008-09

3.  Subacute toxicity of primaquine in dogs, monkeys, and rats.

Authors:  C C Lee; L D Kinter; M H Heiffer
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

4.  Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine.

Authors:  Remington L Nevin
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-04-05       Impact factor: 4.077

Review 5.  Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.

Authors:  Remington L Nevin; Ashley M Croft
Journal:  Malar J       Date:  2016-06-22       Impact factor: 2.979

Review 6.  Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.

Authors:  Jonathan Berman; Tracey Brown; Geoffrey Dow; Stephen Toovey
Journal:  Malar J       Date:  2018-11-06       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.